Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809524 | 1.00 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12908141 | 1.00 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14987109 | 0.91 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL924141 | 0.91 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14987412 | 0.91 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL11067132 | 0.80 | ALOX5 (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL27450040 | 0.80 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL8624823 | 0.80 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12908138 | 0.79 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15449924 | 0.79 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | SYNHALE THERAPEUTICS INC. | 2017-12-28 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-8865718-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | KDM4E 666/4885USP2 1586/4885ALDH1A1 639/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | KDM4E 666/4885USP2 1586/4885ALDH1A1 639/4885 |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | KDM4E 666/4885USP2 1586/4885ALDH1A1 639/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | KDM4E 577/4885USP2 1661/4885ALDH1A1 263/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | KDM4E 666/4885USP2 1586/4885ALDH1A1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.